Amalgamated Bank cut its holdings in shares of Edwards Lifesciences Co. (NYSE:EW – Get Rating) by 1.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 168,382 shares of the medical research company’s stock after selling 2,651 shares during the quarter. Amalgamated Bank’s holdings in Edwards Lifesciences were worth $12,563,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of EW. Trifecta Capital Advisors LLC bought a new stake in shares of Edwards Lifesciences in the 4th quarter valued at approximately $28,000. Addison Advisors LLC increased its holdings in shares of Edwards Lifesciences by 708.0% in the 4th quarter. Addison Advisors LLC now owns 404 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 354 shares during the last quarter. New England Capital Financial Advisors LLC bought a new stake in shares of Edwards Lifesciences in the 4th quarter valued at approximately $42,000. CoreCap Advisors LLC bought a new stake in shares of Edwards Lifesciences in the 4th quarter valued at approximately $44,000. Finally, WASHINGTON TRUST Co grew its stake in Edwards Lifesciences by 252.5% during the 4th quarter. WASHINGTON TRUST Co now owns 698 shares of the medical research company’s stock worth $52,000 after buying an additional 500 shares during the last quarter. 80.35% of the stock is currently owned by hedge funds and other institutional investors.
In related news, VP Jean-Luc M. Lemercier sold 6,640 shares of the stock in a transaction on Wednesday, March 8th. The stock was sold at an average price of $76.96, for a total value of $511,014.40. Following the completion of the sale, the vice president now directly owns 168,875 shares in the company, valued at $12,996,620. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Larry L. Wood sold 6,421 shares of the stock in a transaction dated Wednesday, May 24th. The shares were sold at an average price of $84.23, for a total transaction of $540,840.83. Following the transaction, the insider now owns 213,794 shares of the company’s stock, valued at approximately $18,007,868.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Jean-Luc M. Lemercier sold 6,640 shares of the stock in a transaction dated Wednesday, March 8th. The stock was sold at an average price of $76.96, for a total transaction of $511,014.40. Following the transaction, the vice president now directly owns 168,875 shares in the company, valued at approximately $12,996,620. The disclosure for this sale can be found here. In the last ninety days, insiders sold 189,091 shares of company stock worth $16,232,258. Insiders own 1.29% of the company’s stock.
Analyst Upgrades and Downgrades
Edwards Lifesciences Price Performance
NYSE EW traded up $0.02 on Friday, hitting $81.67. 911,106 shares of the company’s stock were exchanged, compared to its average volume of 3,163,463. The stock has a 50-day moving average of $85.09 and a 200-day moving average of $79.42. The company has a current ratio of 3.01, a quick ratio of 2.17 and a debt-to-equity ratio of 0.10. Edwards Lifesciences Co. has a 52 week low of $67.13 and a 52 week high of $107.92. The stock has a market cap of $49.51 billion, a price-to-earnings ratio of 33.88, a P/E/G ratio of 4.77 and a beta of 1.02.
Edwards Lifesciences (NYSE:EW – Get Rating) last released its earnings results on Wednesday, April 26th. The medical research company reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.61 by $0.01. Edwards Lifesciences had a return on equity of 25.81% and a net margin of 27.07%. The firm had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.39 billion. During the same period in the prior year, the company earned $0.60 earnings per share. The company’s quarterly revenue was up 8.8% on a year-over-year basis. Analysts expect that Edwards Lifesciences Co. will post 2.55 earnings per share for the current year.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care.
- Get a free copy of the StockNews.com research report on Edwards Lifesciences (EW)
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EW – Get Rating).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.